- Home
- PHAR vs VVR Comparison
PHAR vs VVR Comparison
Compare PHAR & VVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- VVR
- Stock Information
- Founded
- PHAR 1988
- VVR 1998
- Country
- PHAR Netherlands
- VVR United States
- Employees
- PHAR N/A
- VVR N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- VVR Trusts Except Educational Religious and Charitable
- Sector
- PHAR Health Care
- VVR Finance
- Exchange
- PHAR Nasdaq
- VVR Nasdaq
- Market Cap
- PHAR 951.7M
- VVR 554.6M
- IPO Year
- PHAR N/A
- VVR N/A
- Fundamental
- Price
- PHAR $14.60
- VVR $3.53
- Analyst Decision
- PHAR Strong Buy
- VVR
- Analyst Count
- PHAR 3
- VVR 0
- Target Price
- PHAR $30.00
- VVR N/A
- AVG Volume (30 Days)
- PHAR 12.7K
- VVR 692.2K
- Earning Date
- PHAR 10-23-2025
- VVR 01-01-0001
- Dividend Yield
- PHAR N/A
- VVR 11.38%
- EPS Growth
- PHAR N/A
- VVR N/A
- EPS
- PHAR N/A
- VVR N/A
- Revenue
- PHAR $339,836,000.00
- VVR N/A
- Revenue This Year
- PHAR $16.63
- VVR N/A
- Revenue Next Year
- PHAR $6.77
- VVR N/A
- P/E Ratio
- PHAR N/A
- VVR N/A
- Revenue Growth
- PHAR 22.44
- VVR N/A
- 52 Week Low
- PHAR $7.31
- VVR $3.55
- 52 Week High
- PHAR $17.08
- VVR $4.38
- Technical
- Relative Strength Index (RSI)
- PHAR 56.71
- VVR 38.62
- Support Level
- PHAR $13.63
- VVR $3.41
- Resistance Level
- PHAR $15.27
- VVR $3.66
- Average True Range (ATR)
- PHAR 0.96
- VVR 0.05
- MACD
- PHAR -0.13
- VVR -0.01
- Stochastic Oscillator
- PHAR 51.83
- VVR 48.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.